Shanghai Obio Technology (Group) Corp., Ltd. (SHA:688238)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Gene Therapy CRO Service	93.23M					36.69M	36.09M	29.35M	-
Gene Therapy CRO Service Growth	-					1.67%	22.95%	-	-
Gene Therapy CDMO Service	135.64M					101.71M	24.83M	12.91M	-
Gene Therapy CDMO Service Growth	-					309.64%	92.31%	-	-
Regenerative Medicine Services	3.85M					-	-	-	-
Biological Agents, Reagents and Others	34.70M					3.91M	1.93M	1.09M	-
Biological Agents, Reagents and Others Growth	-					102.97%	77.34%	-	-
Mechanism and Function Service	-					-	-	-	6.60M
CRO/CDMO/CMO Business	-					-	-	-	443.32K
Merchandise Sales and Others	-					-	-	-	2.56M
Pre-Made Virus Service	-					-	-	-	5.08M
Custom Virus Service	-					-	-	-	13.14M
Total	267.41M					142.31M	62.84M	43.35M	27.83M
Total Growth	-					126.46%	44.98%	55.78%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Eastern Region	130.72M					72.37M	-	-	-
North China	65.44M					10.46M	-	-	-
South China	32.19M					35.75M	-	-	-
Southwest District	11.40M					18.48M	-	-	-
Central China	10.67M					-	-	-	-
Other	14.30M					4.89M	-	-	-
Overseas	2.69M					360.74K	-	-	-
Total	267.41M					142.31M	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 14, 2026

Data Sources Report a data error